Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicines, has announced its participation in the upcoming Guggenheim SMID Cap Biotechnology Conference. Barbara Weber, M.D., the company's President and CEO, will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 10:00 AM ET.
The event will be accessible through a live webcast, available at the provided link and through the company's website under the 'Events & Presentations' section of the Investors page. The presentation recording will remain available on Tango's website for 90 days following the event.
Tango Therapeutics (NASDAQ: TNGX), un'azienda biotecnologica in fase clinica focalizzata su farmaci oncologici di precisione, ha annunciato la sua partecipazione al prossimo Guggenheim SMID Cap Biotechnology Conference. Barbara Weber, M.D., la Presidente e CEO dell'azienda, parteciperà a una chat informale programmata per mercoledì 5 febbraio 2025, alle 10:00 AM ET.
L'evento sarà accessibile tramite una diretta web, disponibile al link fornito e attraverso il sito web dell'azienda nella sezione 'Eventi e Presentazioni' della pagina per gli Investitori. La registrazione della presentazione rimarrà disponibile sul sito di Tango per 90 giorni dopo l'evento.
Tango Therapeutics (NASDAQ: TNGX), una empresa biotecnológica en etapa clínica centrada en medicamentos oncológicos de precisión, ha anunciado su participación en la próxima Conferencia de Biotecnología Guggenheim SMID Cap. Barbara Weber, M.D., la Presidenta y CEO de la empresa, participará en una charla informal programada para miércoles 5 de febrero de 2025, a las 10:00 AM ET.
El evento será accesible a través de una transmisión en vivo, disponible en el enlace proporcionado y a través del sitio web de la empresa en la sección 'Eventos y Presentaciones' de la página de Inversores. La grabación de la presentación estará disponible en el sitio de Tango durante 90 días después del evento.
탱고 치료제(Tango Therapeutics) (NASDAQ: TNGX)는 정밀 암 치료제에 주력하는 임상 단계의 생명공학 회사로, 다가오는 구겐하임 SMID 캡 생명공학 컨퍼런스에 참여할 것이라고 발표했습니다. 바바라 웨버(Barbara Weber), M.D. 는 회사의 회장 겸 CEO로서 2025년 2월 5일 수요일, 오전 10:00 ET에 예정된 대담에 참여할 예정입니다.
이 행사는 제공된 링크와 투자자 페이지의 '이벤트 및 발표' 섹션을 통해 회사 웹사이트에서 라이브 웹캐스트로 액세스할 수 있습니다. 발표 녹화는 행사 이후 90일 동안 탱고의 웹사이트에서 제공됩니다.
Tango Therapeutics (NASDAQ: TNGX), une entreprise de biotechnologie en phase clinique axée sur les médicaments anticancéreux de précision, a annoncé sa participation à la prochaine Conférence Guggenheim SMID Cap en biotechnologie. Barbara Weber, M.D., la Présidente et CEO de l'entreprise, participera à une discussion informelle prévue le mercredi 5 février 2025, à 10h00 ET.
L'événement sera accessible via un webinaire en direct, disponible par le lien fourni et sur le site web de l'entreprise dans la section 'Événements et Présentations' de la page Investisseurs. L'enregistrement de la présentation restera disponible sur le site Web de Tango pendant 90 jours après l'événement.
Tango Therapeutics (NASDAQ: TNGX), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf präzise Krebsmedikamente konzentriert, hat seine Teilnahme an der bevorstehenden Guggenheim SMID Cap Biotechnology Conference bekannt gegeben. Barbara Weber, M.D., die Präsidentin und CEO des Unternehmens, wird an einem gemütlichen Gespräch teilnehmen, das für Mittwoch, den 5. Februar 2025, um 10:00 Uhr ET geplant ist.
Die Veranstaltung wird über ein Live-Webcast zugänglich sein, der über den bereitgestellten Link sowie über die Website des Unternehmens im Bereich 'Veranstaltungen & Präsentationen' auf der Investoren-Seite verfügbar ist. Die Aufzeichnung der Präsentation bleibt 90 Tage nach der Veranstaltung auf der Website von Tango verfügbar.
- None.
- None.
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on Wednesday, February 5, 2025 at 10:00 AM ET.
A live webcast of the fireside chat can be accessed at https://wsw.com/webcast/guggen2/tngx/2036463 and will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Investor Contact:
Daniella Beckman
Chief Financial Officer, Tango Therapeutics
IR@tangotx.com
Media Contact:
Daniella Beckman
Chief Financial Officer, Tango Therapeutics
media@tangotx.com
Source: Tango Therapeutics, Inc.
FAQ
When is Tango Therapeutics (TNGX) presenting at the Guggenheim SMID Cap Biotechnology Conference 2025?
How can investors watch Tango Therapeutics' (TNGX) Guggenheim Conference presentation?
How long will Tango Therapeutics' (TNGX) Guggenheim Conference presentation be available for replay?
Who will represent Tango Therapeutics (TNGX) at the Guggenheim SMID Cap Biotechnology Conference?
